The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Predictors of clinical metastases and survival among nonmetastatic prostate cancer (PC) patients (pts) treated with androgen-deprivation therapy (ADT) in Sweden.
Rohini Khorana Hernandez
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Johan Mesterton
Consultant or Advisory Role - Amgen
Jonas Banefelt
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Jan Stålhammar
No relevant relationships to disclose
Patrik Sobocki
Research Funding - Amgen
Bo-Eric Persson
Employment or Leadership Position - Ferring
Alexander Liede
Employment or Leadership Position - Amgen
Stock Ownership - Amgen